Published in Metabolites on February 23, 2017
The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature (2002) 18.30
Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature (2009) 12.58
Opinion: understanding 'global' systems biology: metabonomics and the continuum of metabolism. Nat Rev Drug Discov (2003) 4.46
Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer (2008) 4.15
Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. Eur Urol (2010) 4.11
Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC). Eur Urol (2012) 4.07
Prostate specific antigen: a decade of discovery--what we have learned and where we are going. J Urol (1999) 3.19
An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid. Brain Res (1982) 2.99
Clinical applications of metabolomics in oncology: a review. Clin Cancer Res (2009) 2.91
Human body fluid proteome analysis. Proteomics (2006) 2.39
Understanding patient and physician perceptions of benign prostatic hyperplasia in Europe: The Prostate Research on Behaviour and Education (PROBE) Survey. Int J Clin Pract (2007) 1.88
Sarcosine in prostate cancer tissue is not a differential metabolite for prostate cancer aggressiveness and biochemical progression. J Urol (2010) 1.82
Meta-analysis of prostate-specific antigen and digital rectal examination as screening tests for prostate carcinoma. J Am Board Fam Pract (2003) 1.65
Nucleobases as supramolecular motifs. Chem Soc Rev (2004) 1.47
Methyl balance and transmethylation fluxes in humans. Am J Clin Nutr (2007) 1.33
Metabolomic signatures of aggressive prostate cancer. Prostate (2013) 1.17
GC/MS-based metabolomic approach to validate the role of urinary sarcosine and target biomarkers for human prostate cancer by microwave-assisted derivatization. Anal Bioanal Chem (2011) 1.06
Efforts to resolve the contradictions in early diagnosis of prostate cancer: a comparison of different algorithms of sarcosine in urine. Prostate Cancer Prostatic Dis (2011) 1.06
A new rule-based algorithm for identifying metabolic markers in prostate cancer using tandem mass spectrometry. Bioinformatics (2008) 0.93
LC-MS-based holistic metabolic profiling. Problems, limitations, advantages, and future perspectives. J Chromatogr B Analyt Technol Biomed Life Sci (2014) 0.93
Sarcosine as a potential prostate cancer biomarker and therapeutic target. Cancer Biol Ther (2010) 0.93
Sample preparation prior to the LC-MS-based metabolomics/metabonomics of blood-derived samples. Bioanalysis (2011) 0.86
Early prostate-specific antigen changes and the diagnosis and prognosis of prostate cancer. Curr Opin Urol (2009) 0.85
Metabolic profiling of human urine by CE-MS using a positively charged capillary coating and comparison with UPLC-MS. Mol Biosyst (2010) 0.84
Development and validation of a HILIC- MS/MS multi-targeted method for metabolomics applications. Electrophoresis (2015) 0.83
Validation study of urinary metabolites as potential biomarkers for prostate cancer detection. Bioanalysis (2012) 0.83
Serum kynurenine/tryptophan ratio is not a potential marker for detecting prostate cancer. Clin Biochem (2014) 0.81
Importance of sarcosine formation in methionine methyl carbon oxidation in the rat. J Nutr (1976) 0.79